Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04984681
Other study ID # K23AT010567S
Secondary ID K23AT010567
Status Completed
Phase N/A
First received
Last updated
Start date March 2, 2022
Est. completion date December 14, 2022

Study information

Verified date February 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In our Supplement Aim we will conduct a two-arm randomized pilot test of the adapted intervention compared to a usual care control group among 30 African American/Black women with HIV (15/arm) to assess the feasibility and acceptability of the mindfulness-based stress reduction among women with HIV with mild cognitive impairment. Feasibility will be assessed by our ability to (1) recruit, randomize, and retain participants and (2) deliver the intervention per the manual, as well as (3) participants adherence to home practices and assignments. Acceptability will be assessed via qualitative data (focus group input regarding participants' satisfaction with the intervention and intent to continue using the practices), as well quantitative data (satisfaction survey).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 14, 2022
Est. primary completion date November 10, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Cisgender females - HIV seropositive - 18 years of age or older - English speaking - An active patient at the local HIV ambulatory clinic in Alabama. - No history of neurological (including dementia diagnosis) - No history of severe psychiatric (e.g., schizophrenia or bipolar disorder) disorders Exclusion Criteria: - Non-English speaking - Appear temporarily impaired (e.g., intoxicated) - Not willing to or legally unable to provide informed consent.

Study Design


Intervention

Behavioral:
Mindfulness
The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
Other:
Usual Care
The control condition will continue receiving usual care or standard of care.

Locations

Country Name City State
United States UAB School of Nursing Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of the mindfulness intervention in women with mild cognitive impairment Feasibility will be assessed through the following: recruitment of 30 participants over a period of 12 weeks (3 months); completion of post-intervention survey and exit interview by 75% of participants; 66% (n=9-10) of participants will attend 6 out of 8 sessions remotely or face-to-face and 50% (n= 7-8) of participants will attend the all-day retreat; and 80% of participants (n=24) will be retained throughout the study. We will assess fidelity with the goal of 80% or greater adherence to the intervention manual. Percent of home practice completed over 8 weeks will be assessed via self-report. Immediately post-intervention or 8 weeks.
Primary Acceptability participants' satisfaction with the intervention including length, content, interventionists, practices, setting, and contextual factors. Immediately post-intervention or 8 weeks.
Primary Neurocognitive Function Speed of information processing, Executive Function, Learning and memory, verbal fluency and everyday functioning. Immediately post-intervention or 8 weeks.
Secondary Medication Adherence Adherence will be measured by the single-item antiretroviral therapy question. Higher scores indicate better antiretroviral therapy adherence. Immediately post-intervention
Secondary Perceived Stress Perceived stress will be measures using the perceived stress scale (PSS), with higher scores indicating higher perceived stress. Immediately post-intervention
Secondary Mental Distress Mood will be assessed using the PHQ-8. Higher scores are indicate increased symptom severity. immediately post-intervention
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2